Crystalline form of omeprazole
AssigneeLek Pharmaceuticals D.D.
InventorsNatasa Milac, Anton Copar, Barbara Podobnik, Andreja Belcic, Alenka Kosak, Brina Ornik, Uros Urleb
Life of this patent
Estimating the term…
Abstract
A novel crystalline form of the substrate known under the chemical name 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfiny]-1H-benzimidazole, and having the generic name omeprazole, hereinafter referred to as omeprozole form C, is disclosed. Further, a process for the preparation of omeprazole form C, a pharmaceutical formulation containing omeprazole form C in admixture with pharmaceutically acceptable excipients and the use of omeprazole form C for treatment of gastrointestinal disorders are disclosed.
Claims15
1-15. (canceled)
Omeprazole form C, characterized in providing an X-ray powder diffraction pattern exhibiting substantially the following d-values:
- d-values
- (Å)
- Relative intensity
- 9.5-9.6
- very strong
- 7.9-8.0
- strong
- 7.4-7.5
- weak
- 7.2
- very strong
- 5.9-6.0
- medium
- 5.6
- medium
- 5.1-5.2
- very strong
- 4.88-4.90
- weak
- 4.81-4.84
- weak
- 4.65-4.67
- medium
- 4.57-4.60
- medium
- 4.48-4.51
- strong
- 4.34-4.36
- medium
- 4.16-4.19
- weak
- 3.94-3.97
- weak
- 3.72-3.73
- strong
- 3.58-3.59
- medium
- 3.46-3.47
- strong
- 3.29-3.30
- medium
- 3.23-3.25
- strong
- 3.19-3.20
- medium
- 3.11-3.12
- weak
- 3.03-3.04
- weak
Omeprazole form C, characterized in comprising characteristic absorption bands by Fourier Transform Infrared Spectroscopy at the wavelengths 1204 cm−1, 1076 cm−1, 1024 cm−1, 1014 cm−1 and 822 cm−1.
Dependencies are inferred from the claim text.